Exane Derivatives’s Lennox International LII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$620 Sell
3
-16
-84% -$3.5K ﹤0.01% 552
2022
Q1
$4.9K Sell
19
-1,194
-98% -$328K ﹤0.01% 700
2021
Q4
$393K Buy
1,213
+30
+3% +$9.37K 0.1% 215
2021
Q3
$348K Buy
1,183
+170
+17% +$55.5K 0.08% 253
2021
Q2
$341K Sell
1,013
-1,145
-53% -$386K 0.08% 256
2021
Q1
$672K Buy
+2,158
New +$625K 0.19% 116
2017
Q3
Sell
-1
Closed -$184 616
2017
Q2
$184 Hold
1
﹤0.01% 543
2017
Q1
$167 Hold
1
﹤0.01% 469
2016
Q4
$153 Sell
1
-126
-99% -$19.2K ﹤0.01% 518
2016
Q3
$19.9K Hold
127
﹤0.01% 363
2016
Q2
$18.1K Sell
127
-5
-4% -$687 ﹤0.01% 337
2016
Q1
$17.8K Sell
132
-95
-42% -$11.8K ﹤0.01% 384
2015
Q4
$28.4K Sell
227
-84
-27% -$10.8K ﹤0.01% 279
2015
Q3
$35.2K Hold
311
﹤0.01% 294
2015
Q2
$33.5K Sell
311
-82
-21% -$9.1K ﹤0.01% 311
2015
Q1
$43.9K Sell
393
-13
-3% -$1.34K ﹤0.01% 321
2014
Q4
$38.6K Buy
+406
New +$36.1K 0.01% 346

Other funds holding LII

Exane Derivatives's LII Position: Q2 2022 in Review

Exane Derivatives reduced its Lennox International (LII) stake by 84% in Q2 2022, selling an estimated $3.5K and leaving 3 shares worth $620. The position accounts for ﹤0.01% of the portfolio, ranked #552.

Exane Derivatives first reported a position in LII in Q4 2014 and has held it in 17 quarters since. The position peaked at $672K in Q1 2021. 390 funds tracked by Wall St. Rank hold LII as of Q2 2022.

  • Exane Derivatives held 3 shares of Lennox International worth $620 as of Q2 2022.
  • Exane Derivatives sold 16 Lennox International shares in Q2 2022, an estimated $3.5K.
  • Lennox International made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #552 holding.
  • Exane Derivatives first reported a position in Lennox International in Q4 2014 and has held it in 17 quarters since.
  • Exane Derivatives's Lennox International position peaked at $672K in Q1 2021.
  • 390 funds tracked by Wall St. Rank held Lennox International as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.